All In Biotech

Drug Trial Radar · NCT02142751

Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli

Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem or Ceftriaxone in the Treatment of Bacteriemic Urinary Infection Due to Multidrug Resistance in E.Coli

Last checked: Nov 19, 2026Latest source record: Aug 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Jul 2014

Primary completion

Dec 2018

Study completion Mar 2019

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Spanish Network for Research in Infectious Diseases
First posted
May 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Enterobacterieaceae (and specially Escherichia coli) showing resistance due to multidrug-resistant Escherichia coli, plasmid mediated AmpC or quinolone resistance caused by chromosomal mechanisms have spread worldwide during the last decades. This is important because many of these isolates are also resistant to other first-line agents such as fluoroquinolones or aminoglycosides, leaving few available options for therapy, and this condition is associated with increased morbidity- mortality and length of hospital stay. While carbapenems are considered the drugs of choice for multidrug-resistant Escherichia coli and AmpC producers, recent data suggests that certain alternatives may be suitable for some types of infections. At the present time, finding therapeutic alternatives to carbapenems and cephalosporins for the treatment of invasive infections due to multidrug-resistant Escherichia coli is critical. Fosfomycin was discovered more than 40 years ago but was not investigated according to present standards, and thus is not used in clinical practice except in desperate situations. It is one of the so-considered neglected antibiotics with high potential interest for the future. With the aim of demonstrate the clinical non-inferiority of intravenous fosfomycin compared to meropenem or ceftriaxone in the treatment of bacteraemic urinary tract infections caused by multidrug-resistant Escherichia coli . The investigators propose a "real practise" randomised, controlled, multicentre phase III clinical trial to compare the clinical and microbiological efficacy and safety of intravenous fosfomycin (4 grammes every 6 hours) with meropenem (1 gramme every 8 hours) or ceftriaxone (1 gramme every 24 hours) as targeted therapy of the previously specified infection; change to oral therapy according to predefined options is allowed in both arms after 5 days. Follow-up for the study is planned up to 60 days.

Conditions

  • Infection Due to ESBL Escherichia Coli

Interventions

  • Fosfomycin sodium intravenousDrug

    4g every 6 hours iv (60 min infusion)

  • Meropenem intravenousDrug

    1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins

  • Ceftriaxone intravenousDrug

    1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical and microbiological cure rateTime frame: Day 5-7 after end of treatment (test of cure)

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Marina Baixa

    Alicante, Spain

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital Parc Salud Mar

    Barcelona, Spain

  • Hospital de la Santa Creu i San Pau

    Barcelona, Spain

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario de Bellvitge

    Barcelona, Spain

  • Hospital de Cruces

    Bilbao, Spain

  • Hospital Universitario de Burgos

    Burgos, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, Spain

  • Hospital Son Espases

    Palma de Mallorca, Spain

  • Hospital Marqués de Valdecilla

    Santander, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

  • Hospital Royo Villanova

    Zaragoza, Spain

  • Hospital Mutua de Terrassa

    Terrassa, Barcelona, Spain

  • Hospital Universitario de Gran Canaria Dr. Negrín

    Las Palmas de Gran Canaria, Gran Canarias, Spain

  • Hospital Arnau de Vilanova

    Vilanova, Lleida, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca

    El Palmar, Murcia, Spain

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Tenerife, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.